Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC262 in relapsed/refractory non-Hodgkin's lymphoma
NCT06285422Phase 1Active, not recruiting
- Sponsor
- Sana Biotechnology
- Start
- Apr 2024
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SC262 in non-Hodgkin lymphoma (NHL), sponsored by Sana Biotechnology. Primary endpoint: Safety and Tolerability of SC262 at 24 months. Started Apr 2024; status: active, not recruiting.
02
Drugs
SC262
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06285422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06285422.